Note: You clicked on an external link, which has been disabled in order to keep your shopping session open.
|Tested species reactivity||Human, Mouse|
|Published species reactivity||Human|
|Host / Isotype||Mouse / IgM|
|Immunogen||Purified recombinant fragment of EphA2 expressed in E. Coli.|
|Contains||0.03% sodium azide|
|Storage Conditions||Store at 4°C short term. For long term storage, store at -20°C, avoiding freeze/thaw cycles.|
|Tested Applications||Dilution *|
|Immunohistochemistry (IHC)||1/200 - 1/1000|
|Western Blot (WB)||1/500 - 1/2000|
* Suggested working dilutions are given as a guide only. It is recommended that the user titrate the product for use in their own experiment using appropriate negative and positive controls.
|Flow Cytometry (Flow)||See 1 publications below|
MA5-15284 targets EphA2 in IHC and WB applications and shows reactivity with Human samples.
The MA5-15284 immunogen is purified recombinant fragment of EphA2 expressed in E. Coli.
EPH receptor A2 (EphA2), with 976-amino acid protein (about 107 kDa), belongs to the ephrin receptor subfamily of the protein-tyrosine kinase family. EphA1, EphA2, EphA3, EphA4, EphA5, EphA6, EphA7, EphA8, EphA10, EphB1, EphB2, EphB3, EphB4 and EphB6 are Eph family receptors for Ephrin family ligands. In normal cells, EphA2 negatively regulates cell growth and invasiveness. EphA2 is overexpressed by many human cancers, and is often associated with poor prognostic features. The clinical significance of the expression of EphA2 was observed in breast, prostate, colon, skin, cervical, ovarian, and lung cancers.EphA2 may serve as a novel target for bladder cancer, colonic adenocarcinoma and ovarian cancer therapy.
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.
Antigenic profiling of glioma cells to generate allogeneic vaccines or dendritic cell-based therapeutics.
MA5-15284 was used in flow cytometry to examine the allogenic glioma cells for the generation of therapeutic vaccines or cellular therapy
|Zhang JG,Eguchi J,Kruse CA,Gomez GG,Fakhrai H,Schroter S,Ma W,Hoa N,Minev B,Delgado C,Wepsic HT,Okada H,Jadus MR||Clinical cancer research : an official journal of the American Association for Cancer Research (13:566)||2007|
ECK; EPHA2; ephrin type-A receptor 2; epithelial cell kinase; epithelial cell receptor protein tyrosine kinase; soluble EPHA2 variant 1; tyrosine-protein kinase receptor ECK; tyrosine-protein kinase receptor MPK-5; tyrosine-protein kinase receptor SEK-2
ARCC2; AW545284; CTPA; CTPP1; CTRCT6; ECK; EPHA2; Myk2; Sek-2; Sek2